Amgen
Executive Summary
Manufactured "over 500,000 doses of recombinant DNA products" in fiscal 1987 (year ended March 31) at its GMP facility, a more than tenfold increase over the previous year, firm's most recent annual report notes. Company is doubling existing capacity with a 20,000 sq. ft. mammalian cell culture facility at its Thousand Oaks, California site, scheduled for completion in the current fiscal year. Firm also plans a 1988 product license application filing for its erythropoietin product EPO.